India’s Zydus Cadila Buys Majority Stake In South Africa’s Simayla Pharmaceuticals
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Indian generic drug firm Zydus Cadila said a wholly-owned unit bought a 70 percent stake in South Africa's Simayla Pharmaceuticals of South Africa at an undisclosed price to expand market share in the cardiovascular, anti-infective, respiratory, gastrointestinal and women's healthcare segments